公开(公告)号：US07517995B2

公开(公告)日：2009-04-14

申请号：US11690356

申请日：2007-03-23

Applicant: Steffen Breitfelder ,  Udo Maier ,  Christoph Hoenke ,  Anne T. Joergensen ,  Alexander Pautsch ,  Trixi Brandl ,  Matthias Grauert ,  Matthias Hoffmann ,  Stefan Scheuerer ,  Klaus Erb ,  Michael Pieper ,  Ingo Pragst

Inventor： Steffen Breitfelder ,  Udo Maier ,  Christoph Hoenke ,  Anne T. Joergensen ,  Alexander Pautsch ,  Trixi Brandl ,  Matthias Grauert ,  Matthias Hoffmann ,  Stefan Scheuerer ,  Klaus Erb ,  Michael Pieper ,  Ingo Pragst

IPC: A61K31/429 ,  C07D513/04

CPC classification number: C07D513/04

Abstract: Disclosed are compounds of general formula (I), wherein the groups R1, R2, Ra and Rb have the meanings given in the claims and specification, the tautomers, racemates, enantiomers, diastereomers and the mixtures thereof, and optionally the pharmacologically acceptable acid addition salts, solvates and hydrates thereof, and processes for preparing these thiazolyl-dihydro-cyclopentapyrazoles and the use thereof as pharmaceutical compositions.

Abstract translation: 公开了通式（I）的化合物，其中基团R 1，R 2，R a和R b具有权利要求书和说明书中给出的含义，互变异构体，外消旋体，对映异构体，非对映异构体及其混合物，以及任选的药理学可接受的酸加成 盐，溶剂合物和水合物，以及制备这些噻唑基 - 二氢环戊吡唑的方法及其作为药物组合物的用途。

公开(公告)号：US06534678B1

公开(公告)日：2003-03-18

申请号：US09303975

申请日：1999-05-03

Applicant: Rudolf Bönsch ,  Dieter Stein ,  Klaus Erb

Inventor： Rudolf Bönsch ,  Dieter Stein ,  Klaus Erb

IPC: C07C5142

CPC classification number: C07C51/412 ,  C07C51/02 ,  C07C51/487 ,  C07C59/255

Abstract: Process for producing tartaric acid from a raw material whose dry matter comprises at least 5 wt% potassium hydrogentartrate wherein the raw material containing potassium hydrogen tartrate (KHT) is mixed with aqueous potassium hydroxide solution in a first reaction stage, where KHT is virtually completely reacted to form dipotassium tartrate (DKT), the aqueous solution containing DKT is then mixed with added acid in a precipitation stage at a pH value of 2.0 to 5.0, to produce a suspension containing crystallized KHT; crystallized KHT is then separated from the suspension, washed with water, and there is produced a solution at least 80 wt-% saturated with KHT and then the potassium is removed, to obtain an aqueous tartaric acid product solution, from which water is then at least partly removed.

Abstract translation: 从干物质包含至少5重量％的氢化酒石酸钾的原料生产酒石酸的方法，其中在第一反应阶段将含有酒石酸氢钾的原料（KHT）与氢氧化钾水溶液混合，其中KHT实际上完全反应 形成酒石酸二钾（DKT），然后在pH值为2.0〜5.0的沉淀阶段将含有DKT的水溶液与添加的酸混合，得到含有结晶KHT的悬浮液; 然后将结晶的KHT从悬浮液中分离，用​​水洗涤，并且产生用KHT饱和至少80wt％的溶液，然后除去钾，得到酒石酸水溶液，然后将水 最少部分删除。

公开(公告)号：US20070259855A1

公开(公告)日：2007-11-08

申请号：US11690360

申请日：2007-03-23

Applicant: Udo Maier ,  Matthias Grauert ,  Matthias Hoffmann ,  Christoph Hoenke ,  Anne Joergensen ,  Alexander Pautsch ,  Trixi Brandl ,  Steffen Breitfelder ,  Stefan Scheuerer ,  Klaus Erb ,  Michael Pieper ,  Ingo Pragst

Inventor： Udo Maier ,  Matthias Grauert ,  Matthias Hoffmann ,  Christoph Hoenke ,  Anne Joergensen ,  Alexander Pautsch ,  Trixi Brandl ,  Steffen Breitfelder ,  Stefan Scheuerer ,  Klaus Erb ,  Michael Pieper ,  Ingo Pragst

IPC: A61K31/429 ,  A61K31/428 ,  A61K31/44 ,  A61K31/517 ,  A61K31/549 ,  A61K31/55 ,  A61K31/551 ,  A61P11/00 ,  A61P17/00 ,  A61P19/00 ,  A61P29/00 ,  A61P31/00 ,  A61P37/00 ,  C07D417/06 ,  C07D513/04

CPC classification number: C07D513/04

Abstract: Disclosed are compounds of general formula (I), wherein the groups R1, R2, Ra and Rb have the meanings given in the claims and specification, the tautomers, racemates, enantiomers, diastereomers and the mixtures thereof, and optionally the pharmacologically acceptable acid addition salts, solvates and hydrates thereof, and processes for preparing these thiazolyl-dihydro-indazoles and the use thereof as pharmaceutical compositions.

Abstract translation: 公开了通式（I）的化合物，其中基团R 1，R 2，R a和R b， SUP>具有权利要求书和说明书中给出的含义，互变异构体，外消旋体，对映异构体，非对映体及其混合物，以及任选的药理学上可接受的酸加成盐，溶剂合物和水合物，以及制备这些噻唑基 - 二氢 - 吲唑的方法和 其作为药物组合物的用途。

公开(公告)号：US20100145041A1

公开(公告)日：2010-06-10

申请号：US12706936

申请日：2010-02-17

Applicant: Trixi BRANDL ,  Udo MAIER ,  Matthias HOFFMANN ,  Stefan SCHEUERER ,  Anne T. JOERGENSEN ,  Alexander PAUTSCH ,  Steffen BREITFELDER ,  Matthias GRAUERT ,  Christoph HOENKE ,  Klaus ERB ,  Michael PIEPER ,  Ingo PRAGST

Inventor： Trixi BRANDL ,  Udo MAIER ,  Matthias HOFFMANN ,  Stefan SCHEUERER ,  Anne T. JOERGENSEN ,  Alexander PAUTSCH ,  Steffen BREITFELDER ,  Matthias GRAUERT ,  Christoph HOENKE ,  Klaus ERB ,  Michael PIEPER ,  Ingo PRAGST

IPC: C07D417/14 ,  C07D413/14 ,  C07D513/04 ,  C07D277/82

CPC classification number: C07D513/04

Abstract: Disclosed are thiazolyl-dihydro-quinazolines of general formula (I) wherein the groups R1 to R4 have the meanings given in the claims and specification, the isomers thereof, and processes for preparing these compounds and their use as pharmaceutical compositions.

Abstract translation: 公开了通式（I）的噻唑基 - 二氢 - 喹唑啉，其中基团R 1至R 4具有权利要求书和说明书中给出的含义，其异构体，以及这些化合物的制备方法及其作为药物组合物的用途。

公开(公告)号：US07311837B2

公开(公告)日：2007-12-25

申请号：US10789704

申请日：2004-02-26

Applicant: Dieter Stein ,  Rudolf Bonsch ,  Klaus Erb

Inventor： Dieter Stein ,  Rudolf Bonsch ,  Klaus Erb

IPC: B01D11/00

CPC classification number: C07C51/02 ,  C07C51/42 ,  C07C59/255

Abstract: In a process for the continuous recovery of free tartaric acid from raw materials containing potassium hydrogentartrate, the same are mixed with water and the potassium hydrogentartrate is dissolved. The process is improved in that the suspension is decanted, the clarified liquid is refiltered, the filtrate is cooled to crystallization temperature under a vacuum, the potassium hydrogentartrate crystals formed are dissolved, the solution is subjected to a cation exchange, and the tartaric acid solution obtained is evaporated.

Abstract translation: 在含有氢化酒石酸钾的原料中连续回收游离酒石酸的方法中，将其与水混合，并溶解氢化酒石酸钾。 改进方法是将悬浮液倾析，将澄清的液体重新过滤，将滤液在真空下冷却至结晶温度，形成的氢化酒石酸钾晶体溶解，将溶液进行阳离子交换，并将酒石酸溶液 获得的蒸发。

公开(公告)号：US06569436B1

公开(公告)日：2003-05-27

申请号：US09166174

申请日：1998-10-05

Applicant: Graham Stephen Le Gros ,  Charles Richard William Beasley ,  John William Holloway ,  Klaus Erb

Inventor： Graham Stephen Le Gros ,  Charles Richard William Beasley ,  John William Holloway ,  Klaus Erb

IPC: A61K3904

CPC classification number: A61K39/04 ,  A61K2039/52 ,  A61K2039/521 ,  A61K2039/544 ,  A61K2039/57

Abstract: This invention is directed to methods of preventing or reducing the severity of asthma or the risk of development of same in an individual. The method relies on administration to the airways of the individual of an immunologically effective dose of a mycobacterium based vaccine. The mycobacteria are effective in inducing a Thl type immune response in the individual.

Abstract translation: 本发明涉及预防或减轻哮喘严重程度或个体发展风险的方法。 该方法依赖于免疫有效剂量的基于分枝杆菌的疫苗对个体的气道施用。 分枝杆菌在个体中诱导Th1型免疫应答是有效的。

公开(公告)号：US08354418B2

公开(公告)日：2013-01-15

申请号：US12351017

申请日：2009-01-09

Applicant: Trixi Brandl ,  Udo Maier ,  Christoph Hoenke ,  Anne T. Joergensen ,  Alexander Pautsch ,  Steffen Breitfelder ,  Matthias Grauert ,  Matthias Hoffmann ,  Stefan Scheuerer ,  Klaus Erb ,  Michael Pieper ,  Ingo Pragst

Inventor： Trixi Brandl ,  Udo Maier ,  Christoph Hoenke ,  Anne T. Joergensen ,  Alexander Pautsch ,  Steffen Breitfelder ,  Matthias Grauert ,  Matthias Hoffmann ,  Stefan Scheuerer ,  Klaus Erb ,  Michael Pieper ,  Ingo Pragst

IPC: C07D239/00 ,  A01N43/54 ,  A61K31/505

CPC classification number: C07D513/04

Abstract: The present invention relates to compounds of general formula (I), wherein the groups A, R1, R2, Ra and Rb have the meanings given in the claims and specification, the tautomers, racemates, enantiomers, diastereomers and the mixtures thereof, and optionally the pharmacologically acceptable acid addition salts, solvates and hydrates thereof, and processes for preparing these thiazolyl-dihydro-quinazolines and the use thereof as pharmaceutical compositions.

Abstract translation: 本发明涉及通式（I）的化合物，其中基团A，R 1，R 2，R a和R b具有权利要求书和说明书中给出的含义，互变异构体，外消旋体，对映体，非对映异构体及其混合物， 其药理学上可接受的酸加成盐，溶剂合物和水合物，以及制备这些噻唑基 - 二氢 - 喹唑啉的方法及其作为药物组合物的用途。

公开(公告)号：US20070244104A1

公开(公告)日：2007-10-18

申请号：US11690362

申请日：2007-03-23

Applicant: Trixi Brandl ,  Udo Maier ,  Matthias Hoffmann ,  Stefan Scheuerer ,  Anne Joergensen ,  Alexander Pautsch ,  Steffen Breitfelder ,  Matthias Grauert ,  Christoph Hoenke ,  Klaus Erb ,  Michael Pieper ,  Ingo Pragst

Inventor： Trixi Brandl ,  Udo Maier ,  Matthias Hoffmann ,  Stefan Scheuerer ,  Anne Joergensen ,  Alexander Pautsch ,  Steffen Breitfelder ,  Matthias Grauert ,  Christoph Hoenke ,  Klaus Erb ,  Michael Pieper ,  Ingo Pragst

IPC: A61K31/541 ,  A61K31/5377 ,  A61K31/519 ,  A61K31/496 ,  A61K31/4745 ,  C07D498/02

CPC classification number: C07D513/04

Abstract: Disclosed are thiazolyl-dihydro-quinazolines of general formula (I) wherein the groups R1 to R4 have the meanings given in the claims and specification, the isomers thereof, and processes for preparing these compounds and their use as pharmaceutical compositions.

Abstract translation: 公开了通式（I）的噻唑基 - 二氢 - 喹唑啉，其中基团R 1至R 4具有权利要求书和说明书中给出的含义，其异构体和 制备这些化合物的方法及其作为药物组合物的用途。

公开(公告)号：US20070238746A1

公开(公告)日：2007-10-11

申请号：US11690355

申请日：2007-03-23

Applicant: Trixi Brandl ,  Udo Maier ,  Christoph Hoenke ,  Anne Joergensen ,  Alexander Pautsch ,  Steffen Breitfelder ,  Matthias Grauert ,  Matthias Hoffmann ,  Stefan Scheuerer ,  Klaus Erb ,  Michael Pieper ,  Ingo Pragst

Inventor： Trixi Brandl ,  Udo Maier ,  Christoph Hoenke ,  Anne Joergensen ,  Alexander Pautsch ,  Steffen Breitfelder ,  Matthias Grauert ,  Matthias Hoffmann ,  Stefan Scheuerer ,  Klaus Erb ,  Michael Pieper ,  Ingo Pragst

IPC: A61K31/519 ,  A61K31/4745 ,  C07D498/02

CPC classification number: C07D513/04

Abstract: Disclosed are compounds of general formula (I), wherein the groups A, R1, R2, Ra and Rb have the meanings given in the claims and specification, the tautomers, racemates, enantiomers, diastereomers and the mixtures thereof, and optionally the pharmacologically acceptable acid addition salts, solvates and hydrates thereof, and processes for preparing these thiazolyl-dihydro-quinazolines and the use thereof as pharmaceutical compositions.

Abstract translation: 公开了通式（I）的化合物，其中基团A，R 1，R 2，R a和R b 具有权利要求和说明书中给出的含义，互变异构体，外消旋体，对映异构体，非对映异构体及其混合物，以及任选的药理学上可接受的酸加成盐，溶剂合物和水合物，以及制备这些噻唑基 - 喹唑啉及其作为药物组合物的用途。

公开(公告)号：US20070238718A1

公开(公告)日：2007-10-11

申请号：US11690351

申请日：2007-03-23

Applicant: Matthias GRAUERT ,  Udo Maier ,  Matthias Hoffmann ,  Stefan Scheuerer ,  Anne Joergensen ,  Alexander Pautsch ,  Trixi Brandl ,  Christoph Hoenke ,  Steffen Breitfelder ,  Klaus Erb ,  Michael Pieper ,  Ingo Pragst

Inventor： Matthias GRAUERT ,  Udo Maier ,  Matthias Hoffmann ,  Stefan Scheuerer ,  Anne Joergensen ,  Alexander Pautsch ,  Trixi Brandl ,  Christoph Hoenke ,  Steffen Breitfelder ,  Klaus Erb ,  Michael Pieper ,  Ingo Pragst

IPC: A61K31/55 ,  A61K31/4747 ,  A61K31/43 ,  C07D498/02

CPC classification number: C07D513/04

Abstract: The present invention relates to new thiazolyl-dihydro-indazoles of general formula (I) wherein the groups R1, R2 and R3 have the meanings given in the claims and specification, the tautomers, racemates, enantiomers, diastereomers and the mixtures thereof, and optionally the pharmacologically acceptable acid addition salts, solvates and hydrates thereof, and processes for preparing these thiazolyl-dihydro-indazoles and the use thereof as pharmaceutical compositions.

Abstract translation: 本发明涉及通式（I）的新的噻唑基 - 二氢 - 吲唑，其中R 1，R 2和R 3基团具有 权利要求和说明书中给出的含义，互变异构体，外消旋物，对映异构体，非对映异构体及其混合物，以及任选的药理学上可接受的酸加成盐，溶剂合物和水合物，以及制备这些噻唑基 - 二氢 - 吲唑的方法及其用途 作为药物组合物。